New Lipid Drugs and Updated Guidelines Expand Statin Eligibility, Redefining Cholesterol Care
Inclisiran lowers LDL by about 49% versus placebo in a meta-analysis and is a twice-yearly option that can be used with or without statins; Lipfendra (enlicitide), the first oral PCSK9 inhibitor, lowered LDL by roughly 56–59% in trials; combined with updated U.S. cholesterol guidelines that may make over half of adults eligible for statin therapy, these developments indicate a shift toward broader, personalized cholesterol management and adherence-friendly therapies.
